Patent intelligence · US
US 10358447
Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same
Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same
Patent details — US 10358447
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 23, 2019
- Expiration
- Jul 18, 2039
- Applicant
- ARBUTUS BIOPHARMA CORPORATION
- Claims
- 24
- CPC classes
- A61K, A61K31/4375, A61K45/06, A61P
Quick answer
US 10358447 (Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same) is held by ARBUTUS BIOPHARMA CORPORATION. Status: granted. Granted Jul 23, 2019. Expires Jul 18, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ARBUTUS BIOPHARMA CORPORATION
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K31/4375, A61K45/06, A61P, A61P31/20
More from ARBUTUS BIOPHARMA CORPORATION
Related pharmaceutical patents in our USPTO index.
-
US 12357705
Negatively charged peg-lipid conjugates
granted -
US 12350383
Cationic lipids containing silicon
granted -
US 12251470
Lipid nanoparticle formulations
granted -
US 12129467
Non-liposomal systems for nucleic acid delivery
granted -
US 12083118
Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
granted -
US 12043833
Targeted compositions
granted -
US 12042541
Lipids and compositions for the delivery of therapeutics
granted -
US 12023383
Lipid compositions
granted
Related coverage
5 Notable Oncology FDA Approvals Granted in May: A B2B Analysis
In May 2026, the FDA granted five major oncology approvals, including a first-in-class combination for non-muscle invasive bladder cancer. This analysis covers the approvals, their competitive impact, and next milestones for pharma teams.
May 2026 FDA Oncology Actions: 8 Approvals Reshape the Landscape
In May 2026, the FDA issued 8 oncology and hematology approvals, including durvalumab for high-risk non-muscle invasive bladder cancer. This analysis covers the approvals, their competitive impact, and what to watch next in FDA oncology guidance.
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
FDA Approves Durvalumab and BCG for High-Risk NMIBC
The FDA has approved Durvalumab and BCG for patients with high-risk non-muscle invasive bladder cancer (NMIBC). This approval marks a significant development in oncology treatment options.
Frequently asked questions
What is US patent 10358447?
US 10358447 (Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same) is held by ARBUTUS BIOPHARMA CORPORATION. Status: granted. Granted Jul 23, 2019. Expires Jul 18, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10358447?
ARBUTUS BIOPHARMA CORPORATION is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 56 pharmaceutical patents for this assignee.
When does US 10358447 expire?
Our index shows an expiration date of Jul 18, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.